8 Jan 2016 07:00
Immunodiagnostic Systems Holdings plc
Relocation of Automated related Assay Activity
Immunodiagnostic Systems Holdings plc ("IDS" or the "Company"), a leading solution provider to the clinical laboratory diagnostic market, is looking to streamline and improve the efficiency of its assay manufacturing and development across the Group. We are proposing to move all automated related activities from our UK manufacturing site to our Belgium manufacturing facility, hence consolidating all automated activity in one location.
Against this background there is a possibility this proposal could result in up to 26 job losses at the UK manufacturing site situated in Boldon. This would reduce the total UK workforce to approximately 95 employees and adjust the total group workforce to 310 employees.
As part of the consultation process, the Company is considering all possible alternatives to reduce the number of potential redundancies, in particular the Company is considering applications from volunteers for redundancy from those employees who are interested. We will continue to work closely with those employees that are affected to ensure they are supported.
This proposal would result in two manual assay manufacturing facilities in both the UK (Boldon) and Italy (Spello). Instrument production and system engineering will be concentrated in France (Pouilly) and one automated assay manufacturing facility, at our Belgium site (Liege), where we continue to invest and expand our R&D capabilities.
For further information:
Immunodiagnostic Systems Holdings plc | Tel : +44 (0)191 519 0660 |
Patricio Lacalle, Chief Executive Officer
| |
Peel Hunt LLP | Tel : +44 (0)207 418 8900 |
James Steel / Tom Burt / Oliver Jackson |